Prosecution Insights
Last updated: May 29, 2026

St. Jude Children's Research Hospital

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 7 days (1)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (17%)
3
Medium (50%)
1
Easy (17%)
1
Unknown (17%)

Rejection Statute Mix

BucketCases
§101 only1 (17%)
§103 only3 (50%)
§112 only1 (17%)
No statute on record1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SALMON, KATHERINE D 1 42.6% +38.0%
TURPIN, ZACHARY MARK 1 0.0% +0.0%
HORTH, LISA ANNE 1 61.8% +44.1%
GRABER, JAMES J 1 46.2% +56.1%
QIAN, CELINE X 1 47.9% +16.8%
MOSS, NATALIE M 1 31.2% +17.2%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17616279 KIT AND METHOD FOR ANALYZING SINGLE T CELLS TURPIN, ZACHARY MARK 225d overdue
17432721 METHODS FOR IDENTIFYING AND IMPROVING T CELL MULTIPOTENCY HORTH, LISA ANNE 37d overdue

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17432721 METHODS FOR IDENTIFYING AND IMPROVING T CELL MULTIPOTENCY HORTH, LISA ANNE 37d overdue
17779841 USE OF PROTEASE SERINE 21 (PRSS21) ANTIGEN TESTING IN THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA SALMON, KATHERINE D 11d overdue
16544180 METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER QIAN, CELINE X 6d
16467358 DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY MOSS, NATALIE M 70d
17258533 USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS GRABER, JAMES J 79d

Top Art Units

Art UnitApps
1682 2
1681 1
1631 1
1637 1
1653 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17779841 USE OF PROTEASE SERINE 21 (PRSS21) ANTIGEN TESTING IN THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA SALMON, KATHERINE D 1682 §103 Non-Final OA 11d overdue Pending May 25, 2022
17616279 KIT AND METHOD FOR ANALYZING SINGLE T CELLS TURPIN, ZACHARY MARK 1682 Other Non-Final OA 225d overdue Pending Dec 03, 2021
17432721 METHODS FOR IDENTIFYING AND IMPROVING T CELL MULTIPOTENCY HORTH, LISA ANNE 1681 §101 Final Rejection 37d overdue Pending Aug 20, 2021
17258533 USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS GRABER, JAMES J 1631 §103 Final Rejection 79d Pending Jan 07, 2021
16544180 METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER QIAN, CELINE X 1637 §112 Final Rejection 6d Pending Aug 19, 2019
16467358 DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY MOSS, NATALIE M 1653 §103 Non-Final OA 70d Pending Jun 06, 2019

Managing St. Jude Children's Research Hospital's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month